Syngene announces senior-level appointments

Alan CollisAlex Del Priore was appointed as Senior Vice President, Manufacturing Services and Alan Collis appointed as Vice President, Integrated Drug Discovery Services 

Syngene International has appointed two senior leaders, Alex Del Priore and Dr Alan Collis, with effect from July 26, 2021. Priore has been appointed as the Senior Vice President, Manufacturing Services. Collis joins as the Vice President, Integrated Drug Discovery Services. They will both be based in the US, which is one of the key markets for the company.  

Priore is a member of the Executive Committee and will provide strategic direction for the growth of the manufacturing services business leveraging the company’s discovery and development strengths for the effective end-to-end offering. He is responsible for the growth of API outcomes from Syngene’s new facility in Mangaluru and will develop a sustainable client base for the business in collaboration with the commercial and business development teams. Priore will also be responsible for the growth of the large molecule operations and will oversee Syngene’s Biologics operations unit to continue building it as a diversified manufacturing business. He reports to Dr Mahesh Bhalgat, Chief Operating Officer. 

Collis will be joining as the leader of the SynVent team. SynVent is Syngene’s platform for integrated discovery and early development, delivering upon strategies built in collaboration with and on behalf of clients to advance novel molecules into clinical trials. He will be responsible for the formulation and implementation of Syngene’s overall Integrated Drug Discovery (IDD) scientific strategy and will oversee the end-to-end execution of client programmes. He reports to Kenneth Barr, Sr Vice President, Discovery Services.

Commenting on the appointments, Jonathan Hunt, MD and CEO, Syngene International, said, “As we continue our rapid growth in the global CRO/CDMO marketplace, these hires align with Syngene’s focus on providing end-to-end solutions for discovery, development, and manufacturing across a range of therapeutic areas and modalities. We look forward to having Alex and Alan on board, which will help strengthen our position as a partner in innovation for our clients and to steer Syngene towards new growth milestones.”

Priore said, “I am delighted to take on my new role at Syngene and contribute towards pushing the boundaries of science in manufacturing and advanced therapies in biologics. As part of an integrated scientific solutions provider for multiple industries, I look forward to the exciting journey.”

Collis said, “I aim to swiftly progress the great scientific insights of our partners into clinical evaluation. The path requires a thoroughly connected and integrated strategy sitting squarely across our multiple proven capabilities in research, development, and manufacturing.”

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Leave a Reply

Back to top button